Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival.

MLA

Dávila, Julio, et al. “Recovery of Polyclonal Immunoglobulins during Treatment in Patients Ineligible for Autologous Stem‐cell Transplantation Is a Prognostic Marker of Longer Progression‐free Survival and Overall Survival.” British Journal of Haematology, vol. 198, no. 2, July 2022, pp. 278–87. EBSCOhost, https://doi.org/10.1111/bjh.18182.

APA

Dávila, J., González, C. V., Escalante, F., Cerdá, S., Puig, N., García, S. R., Bárez, A., Montes, C., López, R., Alonso, J. M., Aguilar, C., García, M. A., Labrador, J., Aguilera, C., García, C. A., Hernández, R., Mateos, M., & Ocio, E. M. (2022). Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival. British Journal of Haematology, 198(2), 278–287. https://doi.org/10.1111/bjh.18182

Chicago

Dávila, Julio, Calle, Verónica González, Fernando Escalante, Seila Cerdá, Noemí Puig, Sanz, Ramón García, Abelardo Bárez, et al. 2022. “Recovery of Polyclonal Immunoglobulins during Treatment in Patients Ineligible for Autologous Stem‐cell Transplantation Is a Prognostic Marker of Longer Progression‐free Survival and Overall Survival.” British Journal of Haematology 198 (2): 278–87. doi:10.1111/bjh.18182.